Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS
Document Type and Number:
WIPO Patent Application WO/2020/162580
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition containing mesenchymal stem cells to be administered to a patient who has undergone stent implantation. Specifically, the present invention relates to: a pharmaceutical composition which is a pharmaceutical composition for tissue repair/regeneration characterized by containing mesenchymal stem cells and being administered to a patient who has undergone stent implantation; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis by the pharmaceutical composition.
More Like This:
Inventors:
HONMOU OSAMU (JP)
SASAKI MASANORI (JP)
SASAKI YUKO (JP)
OKA SHINICHI (JP)
NAKAZAKI MASAHITO (JP)
MAEZAWA RIE (JP)
SASAKI MASANORI (JP)
SASAKI YUKO (JP)
OKA SHINICHI (JP)
NAKAZAKI MASAHITO (JP)
MAEZAWA RIE (JP)
Application Number:
PCT/JP2020/004698
Publication Date:
August 13, 2020
Filing Date:
February 07, 2020
Export Citation:
Assignee:
UNIV SAPPORO MEDICAL (JP)
NIPRO CORP (JP)
NIPRO CORP (JP)
International Classes:
A61P9/10; A61K35/28; A61L27/38; A61L31/16; A61P9/14; A61P41/00; A61P43/00
Domestic Patent References:
| WO2005097147A1 | 2005-10-20 | |||
| WO2002000849A1 | 2002-01-03 | |||
| WO2009034708A1 | 2009-03-19 | |||
| WO2018034023A1 | 2018-02-22 | |||
| WO2018034314A1 | 2018-02-22 | |||
| WO2017188457A1 | 2017-11-02 | |||
| WO2009002503A1 | 2008-12-31 |
Other References:
ZHANG, G. W. ET AL.: "Mechanisms of the protective effects of BMSCs promoted by TMDR with heparinized bFGF-incorporated stent in pig model of acute myocardial ischemia", J. CELL . MOL. MED., vol. 15, no. 5, 2011, pages 1075 - 1086, XP055729939
JIN, G. Z. ET AL.: "IMPLANTATION OF STENT COATED WITH ANTIBODY AGAINST MESENCHYMAL STEM CELLS PREVENTS RESTENOSIS", ACTA MEDICA MEDITERRANEA, vol. 29, 2013, pages 785 - 789, XP055842025
LI, X. ET AL.: "Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on CD 61, CD 62P and CD 54 in Elderly Patients with Old Myocardial Infarction", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, vol. 30, no. 3, 2013, pages 157, XP055842031
WU, X. ET AL.: "Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent", J. BIOMED MATER RES PART A, vol. 98 A, no. 3, 2011, pages 442 - 449, XP055729941
DUSSAILLANT GR ET AL.: "Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis", J AM COLL CARDIOL, vol. 26, 1995, pages 720 - 724, XP029656976, DOI: 10.1016/0735-1097(95)00249-4
HOFFMANN R ET AL.: "Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study", CIRCULATION, vol. 94, 1996, pages 1247 - 1254
LANKFORD KL ET AL.: "Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord", PLOS ONE, vol. 13, 2018, pages e0190358
NAKAZAKI M ET AL.: "Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats", J NEUROSURG, vol. 127, 2017, pages 917 - 926
PROCKOP DJ ET AL.: "Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation", MOL THER, vol. 20, 2012, pages 14 - 20, XP055202750, DOI: 10.1038/mt.2011.211
SHI Y ET AL.: "Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases", NAT REV NEPHROL, 2018
SASAKI Y ET AL.: "Synergic Effects of Rehabilitation and Intravenous Infusion of Mesenchymal Stem Cells After Stroke in Rats", PHYS THER, vol. 96, 2016, pages 1791 - 1798
See also references of EP 3922310A4
JIN, G. Z. ET AL.: "IMPLANTATION OF STENT COATED WITH ANTIBODY AGAINST MESENCHYMAL STEM CELLS PREVENTS RESTENOSIS", ACTA MEDICA MEDITERRANEA, vol. 29, 2013, pages 785 - 789, XP055842025
LI, X. ET AL.: "Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on CD 61, CD 62P and CD 54 in Elderly Patients with Old Myocardial Infarction", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, vol. 30, no. 3, 2013, pages 157, XP055842031
WU, X. ET AL.: "Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent", J. BIOMED MATER RES PART A, vol. 98 A, no. 3, 2011, pages 442 - 449, XP055729941
DUSSAILLANT GR ET AL.: "Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis", J AM COLL CARDIOL, vol. 26, 1995, pages 720 - 724, XP029656976, DOI: 10.1016/0735-1097(95)00249-4
HOFFMANN R ET AL.: "Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study", CIRCULATION, vol. 94, 1996, pages 1247 - 1254
LANKFORD KL ET AL.: "Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord", PLOS ONE, vol. 13, 2018, pages e0190358
NAKAZAKI M ET AL.: "Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats", J NEUROSURG, vol. 127, 2017, pages 917 - 926
PROCKOP DJ ET AL.: "Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation", MOL THER, vol. 20, 2012, pages 14 - 20, XP055202750, DOI: 10.1038/mt.2011.211
SHI Y ET AL.: "Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases", NAT REV NEPHROL, 2018
SASAKI Y ET AL.: "Synergic Effects of Rehabilitation and Intravenous Infusion of Mesenchymal Stem Cells After Stroke in Rats", PHYS THER, vol. 96, 2016, pages 1791 - 1798
See also references of EP 3922310A4
Attorney, Agent or Firm:
UMEDA Shinsuke et al. (JP)
Download PDF:
Previous Patent: METHOD FOR MANUFACTURING ELECTRONIC COMPONENT
Next Patent: CUTTING INSERT AND CUTTING TOOL
Next Patent: CUTTING INSERT AND CUTTING TOOL